Anti-EGFR liečba pri kolorektálnom karcinóme: aká je jej úloha v súčasnosti a budúcnosti? // SOLEN

Onkológia 5/2019

Anti-EGFR treatment in colorectal cancer – what is ist role today and in the future?

Epidermal Growth Factor Receptor (EGFR) was one of the first molecular-biological target utilised in oncology. EGFR overexpression is present in 60-80% of cases of colorectal (CRC). Two anti-EFGR targeted monoclonal antibodies (MoABs) are available at present: cetuximab and panitumumab. Their use is limited for patients with metastatic CRC. According to available data, there is no use for anti-EGFR treatment in neoadjuvant or adjuvant treatment of patients with early- stage CRC. Anti-EGFR MoAbs in combination with chemotherapy can be used as conversion therapy in oligometastatic CRC. Combination of anti-EGFR MoAbs with immunotherapy, re-challenge of anti-EGFR treatment after its previous failure and its combination with BRAF/MEK inhibitors in BRAFV600 -mutant patient appears to be a promising strategy.

Keywords: colorectal cancer, EGFR, cetuximab, panitumumab, RAS, BRAF